Separate studies investigating the relationship of essential hypertension (EH) with the HLA system and with Chlamydia pneumoniae (C. pneumoniae) infection have given conflicting results. Our aim was to clarify these relationships and determine whether the HLA system and C. pneumoniae infection interact with respect to the risk for EH. An association study (110 essential hypertensives and 107 controls) was conducted in a highly homogeneous population in the Balearic Island of Majorca (Spain). Molecular typing of HLA-B and HLA-DRB and quantification of serum levels of IgG antibodies to C. pneumoniae (sIgGa-Cp) were determined. Student's t-test, v 2 -statistics, logistic regression analysis, and general linear model ANOVA were used for statistical analysis. The results showed that EH was related with HLA-DRB3*0202 in the whole study population, and with levels of sIgGa-Cp463.5 BU/ ml in the group of individuals with sIgGa-Cp430 BU/ml (OR (95% CI) adjusted for obesity, familial history of EH and diabetes ¼ 2.06 (1.07-3.97), P ¼ 0.03, and ¼ 4.60 (1.06-19.90), P ¼ 0.04, respectively). The association between EH and sIgGa-Cp was observed in the DRB3*0202( þ ) individuals, but not in the DRB3*0202(À) subgroup (OR (95% CI) ¼ 11.14 (1.92-64.54), P ¼ 0.004, and ¼ 0.98 (0.22-4.43), P ¼ 0.64, respectively (P of the Mantel-Haenszel test for homogeneity of OR ¼ 0.06)). In our population, EH was positively associated with HLA-DRB3*0202 and with high levels of sIgGa-Cp. Moreover, a significant interaction of DRB3*0202 on the effect of sIgGa-Cp was observed, as the association of EH with these antibodies depended on the presence of DRB3*0202.
Introduction
Essential hypertension (EH) is a complex genetic trait 1 as blood pressure (BP) in each individual is due to the combined effects of variation at an indeterminate number of BP-determining genetic loci and environmental factors. One of the genetic systems for which a possible relationship with EH has been considered is the HLA system and this has been documented in linkage studies. 2, 3 However, studies to analyse the possible association between EH and antigens or alleles of the HLA system, mainly HLA-B and HLA-DR, [3] [4] [5] [6] [7] [8] have failed to yield consistent results.
Although not confirmed by other authors, 9 a positive association between Chlamydia pneumoniae (C. pneumoniae) infection and EH has recently been reported. [10] [11] [12] This observation expands the spectrum of cardiovascular diseases in which C. pneumoniae infection, through immune and inflammatory mechanisms, might play a role. 13, 14 Based on these observations and given the paramount importance of the HLA system in the immune response, it is of great interest to clarify the possible relationship of EH with HLA alleles and C. pneumoniae infection, as well as to investigate possible interactions between HLA alleles and C. pneumoniae infection with respect to the EH risk. We carried out a case-control study in which we typed HLA-B, -DRB1, -DRB3, -DRB4 and -DRB5 alleles and determined the serum levels of IgG antibodies to C. pneumoniae (sIgGa-Cp) in a highly homogeneous population in the Balearic Island of Majorca (Spain). Our results showed a positive association of EH with the allele HLA-DRB3*0202 and with high levels of sIgGa-Cp, but no association between sIgGa-Cp and EH was observed unless this allele was present.
Materials and methods

Study subjects
The research protocol of this case-control study was approved by the Institutional Review Committees of the 'Hospital Universitario Son Dureta' and the 'Gerencia Atenció n Primaria de Mallorca (IBSA-LUT)'. All participants (110 cases and 107 controls) gave their written, informed consent.
Participants were identified from medical records at seven public outpatient clinics in villages located throughout Majorca, where over 75% of the attended population were born on the island. The preselected individuals were asked to attend a specific appointment during which a questionnaire containing demographic, lifestyle and health-related issues was filled in, a medical examination including anthropometry and BP measurement was performed, and blood samples for genetic and serological analysis were collected from subjects who were definitively enrolled. Laboratory data were gathered from medical records. The BP was measured manually with a calibrated sphygmomanometer by a skilled health professional; the mean of two BP measurements, separated by more than 1 min, was taken as the BP for that day.
Only hypertensive individuals without evidence of secondary forms of hypertension were eligible. From among these, those patients with severe EH (systolic blood pressure (SBP) repeatedly X160 mmHg, or diastolic blood pressure (DBP) repeatedly X100 mmHg, or those receiving at least two antihypertensive agents) were selected. We chose individuals with severe EH as several previous studies had shown that the relationship between some genetic markers and EH is enhanced in this group of patients, 15 and at least one study reporting a positive association between C. pneumoniae infection and EH was also performed with severe essential hypertensives. 10 Normotensive subjects (SBP repeatedly o140 mmHg and DBP repeatedly o90 mmHg) were selected as controls from among patients who had noncardiovascular symptoms or from individuals who participated in vaccination programmes. Exclusion criteria were known or suspected immunodeficiency, hypergammaglobulinaemia and connective or autoimmune disease. Since neither hypertensive patients nor controls were acutely ill when their blood samples were collected, we did not expect to include a significant number of cases with acute C. pneumoniae infection. As a minimum, both parents and all four grandparents of patients and controls were required to have been born in Majorca. Furthermore, for each participant, both family names (people born in Spain officially have two family names, that of their father, followed by that of their mother, and women maintain these family names when they are married) had to be characteristic of Majorca, and an effort was made to ensure that the patients and controls selected from each village had at least one of the most typical family names from that village. Similar numbers of cases and controls were selected from each outpatient clinic. Cases and controls were age-and sex-matched as far as possible.
Genetic analysis
Generic typing of HLA-DRB1, -DRB3, -DRB4, -DRB5 and -B loci, and high-resolution subtyping of HLA-DRB1, -DRB3, -DRB4 and -DRB5 loci were performed by molecular techniques, as previously described. 16 Serological analysis sIgGa-Cp levels were determined by a commercial quantitative ELISA kit (SeroCP Quant IgG, Savyon Diagnostics Ltd., Israel) that uses as antigen purified elementary bodies from C. pneumoniae (TWAR-183) and gives the results as binding units (BU)/ml. The assays were performed according to the manufacturer's instructions.
From the equivalences with a microimmunofluorescence (MIF) method, these instructions establish that sera with o10 BU/ml are negative.
Statistical analysis
The between-groups comparison of quantitative and categorical variables was carried out by the unpaired Student's t-test and by the w 2 -statistics, respectively. Allele families and alleles of the HLA system, as dichotomous variables, and the level of sIgGa-Cp, as a continuous variable, were tested for association with EH by univariate and multivariate logistic regression analyses. Crude and adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated from the univariate and multivariate logistic regression parameter estimates, respectively. The P-values of the univariate analyses with the HLA system were not corrected by the Bonferroni method for multiple comparisons, 17 mainly because the existence of HLA haplotypes introduced considerable uncertainty about the number of independent tests performed or implied.
The effects of the explanatory variables on BP level were investigated with the general linear model ANOVA with adjustment for treatment, BMI, age and sex.
The association between EH and sIgGa-Cp was also tested by 2 Â 2 tables using Fisher's exact test, after transforming the level of antibodies in a dichotomous variable. The homogeneity of OR obtained from these tables was analysed by the Mantel-Haenszel test.
The association between explanatory variables was measured by the Spearman's rank-correlation coefficient.
Results
Demographic data
Taking into account each participant's two family names, there was a total of 131 different family names in the total study population, all characteristic of Majorca. No differences were observed in the frequency of these family names between patients and controls. In all, 15 family names, representing only 11% of the total (15/131), gave a cumulative frequency of nearly 50%. Moreover, as many as 76% of the study subjects had at least one of these 15 most frequent family names and 20% had two.
Other demographic and clinical data regarding the study subjects are shown in Table 1 . Patients and controls did not differ regarding age, sex distribution, plasma lipid profile, smoking status or prevalence of sedentary lifestyle. Patients had significantly higher BMI, prevalence of obesity (BMI430 kg/m 2 ) and frequency of family history of hypertension than controls. Diabetes was also more frequent in the group of patients than in the control group, but the difference did not reach statistical significance.
Genetic data
Allele families or alleles that were identified in X20 study participants were evaluated for their statistical association with EH. In the univariate analysis of HLA allele families, only DRB3*02 and DRB4*01 were significantly associated with EH. The association of DRB3*02 was due to the allele DRB3*0202, whereas that of DRB4*01 could not be attributed to any particular allele. The association with DRB3*0202 was positive (crude OR ¼ 1.79), which indicates that this allele is a marker of risk for EH, whereas the association with DRB4*01 was negative (crude OR ¼ 0.56) ( Table 2 ). The prevalence (95% CI) of DRB3*0202 was 52.7% (43-62) in hypertensives and 38.3% (29-47) in controls. The clinical conditions that were more frequent in the hypertensive group (obesity, familial history of EH and diabetes) and could act as confounding variables were introduced in multivariate logistic regression analyses to adjust the association of HLA-DRB3*0202 and -DRB4*01 with EH. Table 2 shows the adjusted OR for these genetic factors. Obesity and family history of EH, in this order, were associated with EH in both models, and only HLA-DRB3*0202 was also independently related to the disease. DRB3*0202-positive and DRB3*0202-negative individuals did not differ regarding the demographic and clinical parameters shown in Table 1 (data not shown). However, the proportions of individuals with EH among the DRB3*0202-positive and DRB3*0202-negative subjects were 58.6 and 43.6%, respectively (P ¼ 0.03), and the BP levels after adjustment for BMI, age and sex were significantly higher in the group of DRB3*0202-positive than in the group of DRB3*0202-negative individuals (Table 3) .
Serological data
In the total study population, there were no significant differences between hypertensives and controls, either in the positivity rates for sIgGa-Cp (71.1 and 70.4%, respectively) or in the levels of these antibodies (34.973.5 and 29.372.8 BU/ml, respectively). The lack of association between the sIgGa-Cp level and EH was independent of obesity, familial history of EH, diabetes and DRB3*0202 allele, as assessed in a multivariate logistic regression analysis (Table 2) . Moreover, the analysis of the correlation between the levels of sIgGa-Cp and the levels of BP with adjustment for treatment, BMI, age and sex gave also negative results (P ¼ 0.71 for SBP and P ¼ 0.24 for DBP). However, distribution of individuals according to levels of sIgGa-Cp was not uniform: we observed an inverse relation between the levels of antibodies and their frequencies, and there was a trend towards higher percentages of hypertensive subjects in the groups with the highest levels of antibodies ( Figure 1 ). Consequently, we searched for a minimum threshold to establish a subgroup of individuals in whom the levels of antibodies in patients and controls were significantly different; that was 30 BU/ml. In the 38 patients and 37 controls with sIgGa-Cp above 30 BU/ml, the levels of these antibodies were 66.274.3 and 52.172.9 BU/ml, respectively (P ¼ 0.008), whereas in the remaining subjects the levels were 12.071.5 and 10.171.4 BU/ml, respectively (P ¼ 0.36). Of these 75 individuals, we excluded two patients and one control whose sIgGa-Cp level was higher than its respective mean þ 2s.d. and even mean þ 2.6s.d.; it was considered that these cases might have had acute infection or reinfection just before entry to the study.
The demographic and clinical data, and the frequencies of patients and controls with the different HLA allele families and alleles in the subgroups of individuals with sIgGa-Cp above and below 30 BU/ml (data not shown) were not significantly different from those described above for the whole group of study subjects; specifically, the frequency of patients with the Analysis in the subgroup of individuals with sIgGa-Cp above 30 BU/ml.
Figure 1 Distribution of hypertensive patients (') and controls (&) by levels of IgG antibodies to C. pneumoniae (BU/ml).
Percentages of hypertensive subjects were 48% in the group of individuals with sIgGa-Cp below 60 BU/ml, 59% in the group of individuals with sIgGa-Cp from 60 to 80 BU/ml and 73% in the group of individuals with sIgGa-Cp above 80 BU/ml (w 2 test for trend: test value ¼ 4.29, P ¼ 0.038).
allele HLA-DRB3*0202 was higher than that of the controls in both subgroups, although the difference in the subgroup with sIgGa-Cp above 30 BU/ml (52.8 vs 41.7%) did not reach statistical significance probably due to the reduction in the number of cases.
The lack of relationship between the levels of antibodies to C. pneumoniae and EH in the subgroup of subjects with sIgGa-Cp below 30 BU/ ml, and the positive association between these variables in the subgroup of individuals with sIgGa-Cp above 30 BU/ml, were confirmed by univariate logistic regression analysis ( Table 2 ). In both subgroups, these results were not dependent on the effect of the factors that could act as confounding variables in our population, as assessed in multivariate logistic regression analysis ( Table 2 ). Obesity and family history of EH, in this order, were again the other variables associated with EH in both multivariate models.
Genetic and serological data
By using logistic regression, we analysed the interaction terms 'level of sIgGa-Cp Â HLA allele family or allele' with respect to the EH risk. This analysis included the allele DRB3*0202 and all the remaining allele families or alleles identified in X20 individuals. None showed a significant correlation with the level of sIgGa-Cp; specifically, the Spearman's rank correlation coefficients for the allele DRB3*0202 were 0.12 (P ¼ 0.12) in the total group of study subjects, 0.16 (P ¼ 0.18) in the subgroup of subjects with sIgGa-Cp above 30 BU/ml, and 0.15 (P ¼ 0.15) in the subgroup of subjects with sIgGa-Cp below 30 BU/ml, whereas the levels of sIgGa-Cp in the DRB3*0202-positive and DRB3*0202-negative individuals were 34.773.3 and 27.572.6 BU/ml (P ¼ 0.10) in the total group of study subjects, 60.073.6 and 53.172.7 BU/ml (P ¼ 0.13) in the subgroup of subjects with sIgGa-Cp above 30 BU/ ml, and 13.171.7 and 9.871.3 (P ¼ 0.12) in the subgroup of subjects with sIgGa-Cp below 30 BU/ml. Among the above-mentioned interaction terms, the term 'level of sIgGa-Cp Â DRB3*0202' almost reaches statistical significance in the subgroup of subjects with sIgGa-Cp above 30 BU/ml (OR (95%CI) ¼ 1.01 (0.99-1.03), P ¼ 0.06)), but not in the total study population (P ¼ 0.23) or in the subgroup of subjects with sIgGa-Cp below 30 BU/ ml (P ¼ 0.31). In accordance with this result, we found that in the subgroup of subjects with sIgGa-Cp above 30 BU/ml, the sIgGa-Cp levels were associated with EH in the 34 individuals with the allele DRB3*0202 but not in the 38 individuals DRB3*0202 negative; these results were observed with and without adjustment for obesity, familial history of EH and diabetes (Table 2 ). Figure 2 illustrates that in the subgroup of individuals with sIgGa-Cp above 30 BU/ml, there was a large difference between positive and negative DRB3*0202 subjects with respect to the ratio 'probability of EH/probability of no EH' as a function of the sIgGaCp level (see Figure 2 legend ). Figure 2 also shows that the EH risk (values of the ratio 'probability of EH/probability of no EH' 41) was associated with high levels of sIgGa-Cp (above 60 BU/ml). After categorizing the subjects with sIgGa-Cp above 30 BU/ml by a value of sIgGa-Cp of 63.5 BU/ml, we found that antibody levels over 63.5 BU/ml were significantly associated with EH (OR (95% CI) ¼ 3.31 (1.15-9.52), P ¼ 0.02) and with higher levels of SBP adjusted for BMI, age and sex (Table 3 ). This association with EH was also observed in the group of DRB3*0202-positive (OR (95% CI) ¼ 11.14 (1.92-64.54), P ¼ 0.004) but not in the group of DRB3*0202-negative individuals (OR (95% CI) ¼ 0.98 (0.22-4.43), P ¼ 0.64); the P-value of the Mantel-Haenszel test for homogeneity of the OR corresponding to positive and negative DRB3*0202 subjects was 0.06, indicating that the association of Figure 2 Ratio 'probability of EH/probability of no EH', as a function of the level of sIgGa-Cp taken as a continuous variable, in all subjects (J), in the subjects DRB3*0202 positive (&) and in the subjects DRB3*0202 negative (n). All of these individuals had a level of antibodies above 30 BU/ml. The curves of this figure were calculated using the levels of antibodies of the study subjects and the parameter estimates from the univariate logistic regression models (see Table 2 high levels of sIgGa-Cp with EH was not maintained across the strata defined by DRB3*0202.
Discussion
We describe for the first time a relationship between the allele HLA-DRB3*0202 and C. pneumoniae infection in the context of the EH risk.
Our study had sufficient power to detect at least an association between the allele DRB3*0202 and EH. The methodological problems related to the case-control studies for the genetic dissection of complex traits 1 may explain why studies of this kind on the relationship between EH and the HLA system 3-8 have failed to yield consistent results. In our study, we tried to avoid those problems and we can reasonably state that the association between DRB3*0202 and EH in our population is real.
Our study population is native to Majorca as all its family names were peculiar to this small Mediterranean island; it is noteworthy that some of these family names have been present in Majorca since the 13th century. Moreover, the distribution of these family names is strongly biased towards a few of them. Furthermore, our study population has been free of immigratory influences due to its insularity. Thus, we can conclude that it has a relatively high degree of ethnic homogeneity. As the study participants pertained to small geographic areas on the island in which over 75% of the population were born in Majorca, they share common traditional lifestyle and dietary habits. Such characteristics of our study participants minimize the possibility that the above-mentioned association is an artefact of population admixture, a drawback of the casecontrol studies for the genetic dissection of complex traits. 1 It is unlikely that the association between DRB3*0202 and EH in our study population was due to confounding effects of the clinical conditions that were more frequent in the hypertensive group, as the association was confirmed by multivariate analysis adjusting for these factors. The fact that the genetic factor HLA-DRB3*0202 and a familial history of EH are independent EH risk factors can be explained by the fact that EH is a complex genetic trait:
1 this means that there are a number of other genes or loci that can confer EH susceptibility, and that the effect of HLA-DRB3*0202 on BP level may be obscured by the effects of other genes or environmental factors.
The ethnic homogeneity of our study population might also be important for our work concerning sIgGa-Cp, as it has been proposed that the disagreements regarding the relation between these antibodies and EH 9-11 could be due to the different ethnic origin of the population analysed in each study. 9, 11 The positivity rate for sIgGa-Cp (about 70%) in our total study group (mean age of 61 years) clearly matches the prevalence of these antibodies in wide populations of individuals aged about 60 years in Western countries. 13 This high prevalence can be explained by frequent reinfection or persistent chronic infection by C. pneumoniae, but in any case it reflects a chronic host response against this microorganism.
13 Besides, our data, showing an inverse relation between the levels of sIgGa-Cp and their frequencies, also coincide with the data obtained from large series. 18 In the total study group there were no significant differences between patients and controls, either in the positivity rates for sIgGa-Cp or in the levels of these antibodies. This, however, was not the result of a homogeneous lack of relationship between these antibodies and EH throughout the study population. Rather, it was the consequence of two distinct facts: only at high levels of sIgGa-Cp was there an association of these antibodies with EH, and there was a great preponderance of subjects with low levels of sIgGa-Cp in our study population. When we did not take the individuals with the lowest levels of sIgGa-Cp (below 30 BU/ml) into account in the statistical analysis, we were able to demonstrate the positive relation between these antibodies and EH. Moreover, this association remained after taking into consideration potential confounding factors in our study population (obesity, family history of EH, diabetes and HLA-DRB3*0202).
In this study, we describe in an explicit way that C. pneumoniae infection is associated with EH only when the level of IgG antibodies to the pathogen is high. In agreement with our finding in EH, clinically significant associations with high levels of IgG antibodies to C. pneumoniae, but not with C. pneumoniae infection in which the levels of these antibodies are low, have been described in other cardiovascular diseases. [18] [19] [20] On the basis of these results, Neumann et al 18 who analysed the frequency of restenosis after coronary stenting in relation with the titer of IgG antibodies to C. pneumoniae, suggested that it is not the C. pneumoniae infection as such but the variable host response to infection that affects the clinical end point. We do not know whether the above-mentioned high levels of sIgGa-Cp in our population are the consequence of characteristics of the host response to infection or are the consequence of pathogen peculiarities.
According to our results, where there is a clear influence of the host's characteristics is in the association between high levels of sIgGa-Cp and EH, as this association was only observed in individuals with the allele HLA-DRB3*0202. Our work is the first that describes that the risk for EH associated with C. pneumoniae infection depends on an HLA allele (DRB3*0202), and this is the main finding of our study. Further studies in populations of other ethnic origin are necessary to confirm this finding.
Although the relationship of the HLA system (DRB3*0202 allele) and sIgGa-Cp with EH that we report here have a potential epidemiological value as they may be useful in identifying individuals at risk for EH, they are at the moment only of statistical nature. However, these initial findings may help to elucidate in further studies mechanisms for development of EH. Since the interaction in the risk for EH of one allele of the HLA system (a key element of the immune response) and an infectious agent (C. pneumoniae) has been described in our study, the probability that immune and inflammatory mechanisms are important factors in the pathogenesis of EH (as has been well documented in atherosclerosis at the cellular 21 and biochemical level 22 ) is clearly higher than that previously suspected. On the basis of several experimental findings, [23] [24] [25] [26] [27] [28] it has been hypothesized that chronic C. pneumoniae infection of the vessels may induce a chronic immune response orchestrated by cytokines and mediated by reactive oxygen intermediates. This may result in increased vascular resistance and lead to increased blood pressure. 11 According to our results, HLA-DRB3*0202 might modulate the individual chronic response to C. pneumoniae infection in such a way that this infection tends to provoke EH in the presence of DRB3*0202 but not in the absence of this allele. This might be one of the possible mechanisms to explain our finding that HLA-DRB3*0202 is a risk factor for EH. In support of this hypothesis, some influences of HLA alleles on the consequences of infections by microorganisms related to C. pneumoniae have been described. For example, the development of pelvic inflammatory disease in infection due to Chlamydia trachomatis has been indirectly linked to HLA-DQA1*0401 and HLA-DQB1*0402, 29 and in infection by Helicobacter pylori, a microorganism that has also been related with vascular diseases, 14 the type of gastric pathology developed partially depends on the host's HLA class II alleles. 30 These associations may be expressions of disease susceptibility linked to HLA molecules; because HLA molecules function as antigen presenting structures, the particular set of HLA molecules expressed by an individual influences its functional T-cell repertoire, and for this reason HLA partly determines the individual response to antigens. Table 4 summarizes what our work adds to the previous knowledge on the topics of the relationship of EH with the HLA system and with C. pneumoniae infection. By using an homogeneous population and taking into consideration potential confounding factors, we confirm that EH may be associated with HLA alleles (DRB3*0202 in our population) C. pneumoniae infection and EH Association between EH and chronic C. pneumoniae infection has been reported
We report that C. pneumoniae infection is associated with EH only when the level of antibodies to the pathogen is high: possible involvement in this association of characteristics of the host response to infection Interactions between HLA system and C. pneumoniae infection in EH
Nothing
We demonstrate for the first time that the association of C. pneumoniae infection with EH depends on the presence in the host of an HLA allele (DRB3*0202): this has possible important pathophysiological consequences
